A platform that goals to vary outcomes for canines identified with most cancers not too long ago acquired $10 million in new funding that can enable the corporate to develop and provides extra canines entry to precision therapy.
FidoCure makes use of genetic testing to establish what genetic mutation is likely to be behind a canine’s most cancers. As soon as testing is full, FidoCure presents precision medication reviews with suggestions for individualized, focused remedy utilizing the most recent science accessible in each human and canine oncology. FidoCure is accessible nationwide via greater than 200 collaborating veterinarians.
To study extra, go to fidocure.com.